JFA
NBIX icon

JNBA Financial Advisors’s Neurocrine Biosciences NBIX Stock Holding History

JNBA Financial Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-200
Closed -$10K – 1019
2016
Q3 		$10K Buy
+200
New +$9.96K ﹤0.01% 1021

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JNBA Financial Advisors's NBIX Position: Q4 2016 in Review

JNBA Financial Advisors sold out of Neurocrine Biosciences (NBIX) in Q4 2016, closing a stake of 200 shares — an estimated $10K sold.

JNBA Financial Advisors first reported a position in NBIX in Q3 2016 and held it in 1 quarter. The position peaked at $10K in Q3 2016. 225 funds tracked by Wall St. Rank hold NBIX as of Q4 2016.

  • JNBA Financial Advisors reported no remaining Neurocrine Biosciences position as of Q4 2016 after selling out during the quarter.
  • JNBA Financial Advisors sold 200 Neurocrine Biosciences shares in Q4 2016, an estimated $10K.
  • JNBA Financial Advisors first reported a position in Neurocrine Biosciences in Q3 2016 and held it in 1 quarter.
  • JNBA Financial Advisors's Neurocrine Biosciences position peaked at $10K in Q3 2016.
  • 225 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2016.

Based on JNBA Financial Advisors's 13F filing for Q4 2016, filed 3 Feb 2017.